The Tara Miller Melanoma Foundation was established in 2014 by Tara Miller, a vibrant and generous young attorney diagnosed with melanoma at the age of 28. Faced with alarming statistics and limited treatment options, Tara was driven to create a foundation that would prevent others from experiencing the same uncertainty and fear. Her vision was to empower research, believing that scientific advancement held the key to changing the odds for melanoma patients and ultimately finding a cure. Tragically, Tara lost her battle with melanoma on October 14, 2014, at the age of 29. However, her legacy continues to inspire and drive the Foundation's mission.
Tara's life was marked by extraordinary strength, positivity, and an infectious love for life, coupled with remarkable humor and wit. Her personal mottoes, "making the best of it" and "finding the silver lining," served as a constant source of inspiration to those around her. Each year, the Foundation proudly celebrates Tara's spirit and attitude at its premiere fundraising event, the annual Make the Best of it Bash.
Tara's passion and selflessness profoundly impacted everyone who heard her story. She made it unequivocally clear that, despite her personal outcome, the Foundation's primary objective was to tirelessly fund research aimed at discovering better treatment options and a definitive cure for melanoma. Her enduring legacy is one of courage and a deep commitment to advancing melanoma research and patient care.
The Tara Miller Melanoma Center at the Abramson Cancer Center
In honor of Tara Miller's vision and with generous support from Debbie and George Miller, The Tara Miller Melanoma Center was established in 2019 at the Abramson Cancer Center of the University of Pennsylvania. This comprehensive center integrates research, clinical care, education, and outreach programs to significantly improve the lives of patients battling melanoma. Despite considerable progress in melanoma therapy, current treatments do not guarantee a cure for all patients, and many continue to suffer and succumb to the disease. The Center is dedicated to providing exceptional, personalized care to all patients with melanoma and other skin cancers through a multidisciplinary approach.
The Center's approach involves close collaboration among specialists from Dermatology, Medical Oncology, Surgical Oncology, Radiation Oncology, and Pathology. Furthermore, it fosters partnerships with basic, translational, and population scientists who are at the forefront of developing new strategies for melanoma prevention, diagnosis, and treatment. The Tara Miller Melanoma Center actively supports innovative research initiatives designed to fundamentally alter the disease's trajectory for individual patients.
Advancing Melanoma Research and Treatment
The Tara Miller Melanoma Foundation has been instrumental in funding significant advancements in melanoma research. Since its inception in 2014, the Foundation has directed over $8.7 million towards crucial research efforts. In a testament to its commitment, the Foundation has supported initiatives such as a Young Investigator Award, established as part of a Melanoma Research Alliance Team Science Award at Penn Medicine. This award, funded over a three-year period, exemplifies the Foundation's dedication to fostering the next generation of melanoma researchers.
The impact of the research funded by the Foundation, including that of MRA Young Investigators, has spurred the exploration of novel combinations of radiation and immune checkpoint blockade therapies. These investigations aim to combat drug resistance and ultimately enhance therapeutic approaches for melanoma patients, aligning directly with Tara's vision of finding improved treatments.
As Dr. Lynn Schuchter, MD, the Madlyn and Leonard Abramson Professor of Clinical Oncology and director of the Tara Miller Melanoma Center, has noted, progress is being made. For instance, Drs. Tara Mitchell and George Mo have published findings in Nature Cancer highlighting the effectiveness of single-agent pembrolizumab for both advanced/metastatic and resectable desmoplastic melanoma. Additionally, the availability of TIL (Tumor-Infiltrating Lymphocyte) therapy at Penn for eligible patients with advanced/metastatic melanoma represents another significant step forward in immunotherapy.
Tara Miller's Personal Journey and Inspiration
Tara Miller's journey was defined by an indomitable will to live, marked by both unconventional strength and a profound realism. Despite facing a devastating diagnosis, she approached her 15-month treatment process with unwavering optimism, humor, and a determination not to let cancer define her. Her resilience shone through five brain surgeries, multiple forms of chemotherapy, and extensive radiation therapy.
Tara's unique approach to life and illness was evident in her collection of symbolic trinkets and her ability to find moments of joy even amidst difficult circumstances. Her sister Kristi recalls Tara's remarkable capacity to cheer others up, often through thoughtful gifts, even when facing personal adversity. Tara's determination to live fully extended to planning travel and social events, reassuring her loved ones that there was no need for fear or doubt.
During an award ceremony for courage, Tara articulated her philosophy: "One of the hardest parts about having cancer is that you have no control over it; I cannot control how my body will respond, what my scans show or how to stop the disease from spreading. However, I can control how I choose to deal with these obstacles." This sentiment guided her through treatment side effects and inspired her to maintain a vibrant social life, engaging in lunch outings and shopping trips with her family.
Tara's adage, "make the best of it," encapsulated her philosophy for confronting her illness. She quickly became a muse to her family and a galvanizing force for a supportive community through an online journal. Her decision to establish the Tara Miller Melanoma Foundation was a personal crusade to advance research for effective treatments and ultimately a cure for melanoma.
At an early fundraising event, Tara shared a powerful perspective: "I have stage IV melanoma. Seventy-five percent of the people diagnosed are dead within a year. I’m at 11 months. Though we cannot change what the statistics of melanoma have been, we can choose to make the best of it and help change where they are going."
Partnerships and Funding Philosophy
Tara Miller's forward-thinking attitude led her to engage with research funding models like that of the Melanoma Research Alliance (MRA). After meeting MRA founder Debra Black, Tara was inspired by their distinctive approach to funding research. Her twin sister, Lauren, recalled Tara's desire to work for MRA upon her recovery, deeply moved by Debra's description of MRA's collaborative funding model, which emphasizes collective participation and sharing of research developments among leaders from academia, industry, and government.
The Millers embraced this philosophy, ensuring that 100% of every dollar donated to their Foundation directly supports research by covering all event costs themselves. This conviction in MRA's mission led them to fund a significant Young Investigator Award, contributing to a Melanoma Research Alliance Team Science Award at Penn Medicine. This commitment underscores their dedication to advancing melanoma research and patient care at Penn Medicine's Abramson Cancer Center.
George Miller, Tara's father, emphasizes the importance of supporting researchers: "Supporting researchers is the most significant thing we as a nonprofit can do to honor Tara’s memory. Because MRA identifies premier researchers in the field, the impact of funding is magnified and the duplication of efforts is eliminated." The Millers' support aims to enable dedicated research teams to translate scientific discoveries into innovative therapies and develop clinical trials that will ultimately change the course of melanoma for future patients.
Recognition and Future Outlook
The Tara Miller Melanoma Center has received national recognition for its commitment to advancing cancer research. The National Cancer Institute has awarded the Center its highest rating, "outstanding," for its cancer research program. Located within the Abramson Cancer Center in Philadelphia, the Center utilizes state-of-the-art diagnostic tools and innovative resources from across Penn Medicine to detect cancers in their earliest stages and provide advanced treatment options for all types of melanomas.
In addition to improving patient care, the Center is dedicated to patient education, guiding individuals on risk reduction strategies and providing regular monitoring. The Tara Miller Melanoma Foundation, founded by Tara a few months before her passing, has successfully raised over $3 million in vital research funding for Penn Medicine's Abramson Cancer Center. This ongoing work, supported by a generous gift from Tara's parents, George and Debbie, stands as a powerful testament to Tara Miller's enduring passion, vision, and voice in the fight against melanoma.
Advocacy Days - Leah Adams
tags: #tara #miller #melanoma #foundation